Arrowhead Pharmaceuticals Receives $200 Million Milestone Payment from Sarepta Therapeutics for ARO-DM1 Progress

Glass Lewis and Egan-Jones recommend Tiptree shareholders vote against the proposed sale of Fortegra to DB Insurance. Both firms cite concerns about the transaction structure, management incentives, and lack of a clear plan for returning nearly $1 billion in transaction proceeds to shareholders. They note that the deal leaves Tiptree with significant discretion over the cash and that the market does not believe the deal is good for shareholders.